| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| - - | HOLD | 0 @ USD 0 | USD 0 | |
| FDMT - 4D Molecular Therapeutics Inc | HOLD | 0 @ USD 9.21001 | USD 0 | The current share valuation price of FDMT based on adjusted close was USD 9.21001. The average price that FDMT shares were previous bought at was USD 7.76202. The current market price is 18.7% higher than average price they were purchased at. The value of the holding in FDMT has fallen by USD 85,015 compared to the previous valuation of 4D Molecular Therapeutics Inc |
| THRD - Third Harmonic Bio Inc. | HOLD | 0 @ USD 0.0300173 | USD 0 | The current share valuation price of THRD based on adjusted close was USD 0.0300173. The average price that THRD shares were previous bought at was USD 5.06885. The current market price is -99.4% lower than average price they were purchased at. USD 0 compared to the previous valuation of Third Harmonic Bio Inc. however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| OKUR - OKUR | SELL | -105 @ USD 2.94005 | USD -309 | The ETF sold 105 shares of OKUR on 2025-12-17. The shares were previously bought for an average price of USD 5.56734. The OKUR shares were sold for -47.2% lower than average price of previous purchases. This resulted in an overall loss of USD 276 The average price that the ETF previously sold OKUR share for is USD 4.52574 which is higher than the selling price of USD 2.94005 on 2025-12-17. |
| STRO - Sutro Biopharma | SELL | -65 @ USD 9.12992 | USD -593 | The ETF sold 65 shares of STRO on 2025-12-17. The shares were previously bought for an average price of USD 1.03176. The Sutro Biopharma shares were sold for 784.9% higher than average price of previous purchases. This sale made a profit of USD 526 The average price that the ETF previously sold STRO share for is USD 7.54372 so the ETF has sold 65 shares on 2025-12-17 at a higher price than the previous selling average. |
| PLRX - Pliant Therapeutics Inc | SELL | -500 @ USD 1.22001 | USD -610 | The ETF sold 500 shares of PLRX on 2025-12-17. The shares were previously bought for an average price of USD 1.47912. The Pliant Therapeutics Inc shares were sold for -17.5% lower than average price of previous purchases. This resulted in an overall loss of USD 130 The average price that the ETF previously sold PLRX share for is USD 6.33063 which is higher than the selling price of USD 1.22001 on 2025-12-17. |
| BMEA - Biomea Fusion Inc | SELL | -600 @ USD 1.35 | USD -810 | The ETF sold 600 shares of BMEA on 2025-12-17. The shares were previously bought for an average price of USD 1.51319. The Biomea Fusion Inc shares were sold for -10.8% lower than average price of previous purchases. This resulted in an overall loss of USD 98 The average price that the ETF previously sold BMEA share for is USD 2.97763 which is higher than the selling price of USD 1.35 on 2025-12-17. |
| MGNX - MacroGenics Inc | SELL | -535 @ USD 1.61 | USD -861 | The ETF sold 535 shares of MGNX on 2025-12-17. The shares were previously bought for an average price of USD 1.52908. The MacroGenics Inc shares were sold for 5.3% higher than average price of previous purchases. This sale made a profit of USD 43 The average price that the ETF previously sold MGNX share for is USD 2.16321 which is higher than the selling price of USD 1.61 on 2025-12-17. |
| FATE - Fate Therapeutics Inc | SELL | -950 @ USD 1.05 | USD -998 | The ETF sold 950 shares of FATE on 2025-12-17. The shares were previously bought for an average price of USD 1.1465. The Fate Therapeutics Inc shares were sold for -8.4% lower than average price of previous purchases. This resulted in an overall loss of USD 92 The average price that the ETF previously sold FATE share for is USD 1.02707 so the ETF has sold 950 shares on 2025-12-17 at a higher price than the previous selling average. |
| MRSN - Mersana Therapeutics Inc | SELL | -40 @ USD 29.06 | USD -1,162 | The ETF sold 40 shares of MRSN on 2025-12-17. The shares were previously bought for an average price of USD 1.31897. The Mersana Therapeutics Inc shares were sold for 2,103.2% higher than average price of previous purchases. This sale made a profit of USD 1,110 The average price that the ETF previously sold MRSN share for is USD 5.9699 so the ETF has sold 40 shares on 2025-12-17 at a higher price than the previous selling average. |
| ALEC - Alector Inc | SELL | -920 @ USD 1.35 | USD -1,242 | The ETF sold 920 shares of ALEC on 2025-12-17. The shares were previously bought for an average price of USD 1.70509. The Alector Inc shares were sold for -20.8% lower than average price of previous purchases. This resulted in an overall loss of USD 327 The average price that the ETF previously sold ALEC share for is USD 1.9137 which is higher than the selling price of USD 1.35 on 2025-12-17. |
| MXCT - MaxCyte Inc | SELL | -925 @ USD 1.48999 | USD -1,378 | The ETF sold 925 shares of MXCT on 2025-12-17. The shares were previously bought for an average price of USD 1.99956. The MaxCyte Inc shares were sold for -25.5% lower than average price of previous purchases. This resulted in an overall loss of USD 471 The average price that the ETF previously sold MXCT share for is USD 2.75736 which is higher than the selling price of USD 1.48999 on 2025-12-17. |
| HUMA - Humacyte Inc | SELL | -1,415 @ USD 1.07 | USD -1,514 | The ETF sold 1415 shares of HUMA on 2025-12-17. The shares were previously bought for an average price of USD 1.98857. The Humacyte Inc shares were sold for -46.2% lower than average price of previous purchases. This resulted in an overall loss of USD 1,300 The average price that the ETF previously sold HUMA share for is USD 2.7324 which is higher than the selling price of USD 1.07 on 2025-12-17. |
| ARCT - Arcturus Therapeutics Holdings Inc | SELL | -245 @ USD 6.52 | USD -1,597 | The ETF sold 245 shares of ARCT on 2025-12-17. The shares were previously bought for an average price of USD 12.4562. The Arcturus Therapeutics Holdings Inc shares were sold for -47.7% lower than average price of previous purchases. This resulted in an overall loss of USD 1,454 The average price that the ETF previously sold ARCT share for is USD 14.2644 which is higher than the selling price of USD 6.52 on 2025-12-17. |
| VYGR - Voyager Therapeutics Inc | SELL | -445 @ USD 4.26 | USD -1,896 | The ETF sold 445 shares of VYGR on 2025-12-17. The shares were previously bought for an average price of USD 3.93356. The Voyager Therapeutics Inc shares were sold for 8.3% higher than average price of previous purchases. This sale made a profit of USD 145 The average price that the ETF previously sold VYGR share for is USD 4.69427 which is higher than the selling price of USD 4.26 on 2025-12-17. |
| EDIT - Editas Medicine Inc | SELL | -830 @ USD 2.37 | USD -1,967 | The ETF sold 830 shares of EDIT on 2025-12-17. The shares were previously bought for an average price of USD 2.61551. The Editas Medicine Inc shares were sold for -9.4% lower than average price of previous purchases. This resulted in an overall loss of USD 204 The average price that the ETF previously sold EDIT share for is USD 2.0221 so the ETF has sold 830 shares on 2025-12-17 at a higher price than the previous selling average. |
| OABI - OmniAb Inc. | SELL | -1,075 @ USD 2.06 | USD -2,215 | The ETF sold 1075 shares of OABI on 2025-12-17. The shares were previously bought for an average price of USD 1.88823. The OmniAb Inc. shares were sold for 9.1% higher than average price of previous purchases. This sale made a profit of USD 185 The average price that the ETF previously sold OABI share for is USD 2.72879 which is higher than the selling price of USD 2.06 on 2025-12-17. |
| AVIR - Atea Pharmaceuticals Inc | SELL | -725 @ USD 3.18 | USD -2,306 | The ETF sold 725 shares of AVIR on 2025-12-17. The shares were previously bought for an average price of USD 3.25167. The Atea Pharmaceuticals Inc shares were sold for -2.2% lower than average price of previous purchases. This resulted in an overall loss of USD 52 The average price that the ETF previously sold AVIR share for is USD 3.14577 so the ETF has sold 725 shares on 2025-12-17 at a higher price than the previous selling average. |
| ACIU - AC Immune Ltd | SELL | -870 @ USD 2.94 | USD -2,558 | The ETF sold 870 shares of ACIU on 2025-12-17. The shares were previously bought for an average price of USD 2.56758. The AC Immune Ltd shares were sold for 14.5% higher than average price of previous purchases. This sale made a profit of USD 324 The average price that the ETF previously sold ACIU share for is USD 2.36036 so the ETF has sold 870 shares on 2025-12-17 at a higher price than the previous selling average. |
| ALLO - Allogene Therapeutics Inc | SELL | -1,905 @ USD 1.42 | USD -2,705 | The ETF sold 1905 shares of ALLO on 2025-12-17. The shares were previously bought for an average price of USD 1.34689. The Allogene Therapeutics Inc shares were sold for 5.4% higher than average price of previous purchases. This sale made a profit of USD 139 The average price that the ETF previously sold ALLO share for is USD 1.81539 which is higher than the selling price of USD 1.42 on 2025-12-17. |
| BCYC - Bicycle Therapeutics Ltd | SELL | -405 @ USD 6.95001 | USD -2,815 | The ETF sold 405 shares of BCYC on 2025-12-17. The shares were previously bought for an average price of USD 8.15555. The Bicycle Therapeutics Ltd shares were sold for -14.8% lower than average price of previous purchases. This resulted in an overall loss of USD 488 The average price that the ETF previously sold BCYC share for is USD 10.4716 which is higher than the selling price of USD 6.95001 on 2025-12-17. |
| AVXL - Anavex Life Sciences Corp | SELL | -745 @ USD 3.91999 | USD -2,920 | The ETF sold 745 shares of AVXL on 2025-12-17. The shares were previously bought for an average price of USD 8.07409. The Anavex Life Sciences Corp shares were sold for -51.4% lower than average price of previous purchases. This resulted in an overall loss of USD 3,095 The average price that the ETF previously sold AVXL share for is USD 9.21493 which is higher than the selling price of USD 3.91999 on 2025-12-17. |
| AUTL - Autolus Therapeutics Ltd | SELL | -1,890 @ USD 1.56 | USD -2,948 | The ETF sold 1890 shares of AUTL on 2025-12-17. The shares were previously bought for an average price of USD 1.74199. The Autolus Therapeutics Ltd shares were sold for -10.4% lower than average price of previous purchases. This resulted in an overall loss of USD 344 The average price that the ETF previously sold AUTL share for is USD 2.07672 which is higher than the selling price of USD 1.56 on 2025-12-17. |
| RCKT - Rocket Pharmaceuticals Inc | SELL | -925 @ USD 3.27 | USD -3,025 | The ETF sold 925 shares of RCKT on 2025-12-17. The shares were previously bought for an average price of USD 4.6478. The Rocket Pharmaceuticals Inc shares were sold for -29.6% lower than average price of previous purchases. This resulted in an overall loss of USD 1,274 The average price that the ETF previously sold RCKT share for is USD 8.49652 which is higher than the selling price of USD 3.27 on 2025-12-17. |
| HCM - HUTCHMED China Ltd | SELL | -275 @ USD 13.26 | USD -3,647 | The ETF sold 275 shares of HCM on 2025-12-17. The shares were previously bought for an average price of USD 15.1543. The HUTCHMED China Ltd shares were sold for -12.5% lower than average price of previous purchases. This resulted in an overall loss of USD 521 The average price that the ETF previously sold HCM share for is USD 15.0922 which is higher than the selling price of USD 13.26 on 2025-12-17. |
| HCM - Hitachi Construction Machinery Co. Ltd | SELL | -275 @ USD 13.26 | USD -3,647 | The ETF sold 275 shares of HCM on 2025-12-17. The shares were previously bought for an average price of USD 15.1543. The Hitachi Construction Machinery Co. Ltd shares were sold for -12.5% lower than average price of previous purchases. This resulted in an overall loss of USD 521 The average price that the ETF previously sold HCM share for is USD 15.0922 which is higher than the selling price of USD 13.26 on 2025-12-17. |
| ALT - Altitude Group Plc | SELL | -735 @ USD 5.09001 | USD -3,741 | The ETF sold 735 shares of ALT on 2025-12-17. The shares were previously bought for an average price of USD 5.14417. The Altitude Group Plc shares were sold for -1.1% lower than average price of previous purchases. This resulted in an overall loss of USD 40 The average price that the ETF previously sold ALT share for is USD 4.69823 so the ETF has sold 735 shares on 2025-12-17 at a higher price than the previous selling average. |
| LXRX - Lexicon Pharmaceuticals Inc | SELL | -3,255 @ USD 1.15 | USD -3,743 | The ETF sold 3255 shares of LXRX on 2025-12-17. The shares were previously bought for an average price of USD 1.15741. The Lexicon Pharmaceuticals Inc shares were sold for -0.6% lower than average price of previous purchases. This resulted in an overall loss of USD 24 The average price that the ETF previously sold LXRX share for is USD 0.772216 so the ETF has sold 3255 shares on 2025-12-17 at a higher price than the previous selling average. |
| VNDA - Vanda Pharmaceuticals Inc | SELL | -550 @ USD 6.81999 | USD -3,751 | The ETF sold 550 shares of VNDA on 2025-12-17. The shares were previously bought for an average price of USD 4.93606. The Vanda Pharmaceuticals Inc shares were sold for 38.2% higher than average price of previous purchases. This sale made a profit of USD 1,036 The average price that the ETF previously sold VNDA share for is USD 4.76894 so the ETF has sold 550 shares on 2025-12-17 at a higher price than the previous selling average. |
| SIGA - SIGA Technologies Inc | SELL | -605 @ USD 6.38 | USD -3,860 | The ETF sold 605 shares of SIGA on 2025-12-17. The shares were previously bought for an average price of USD 6.6331. The SIGA Technologies Inc shares were sold for -3.8% lower than average price of previous purchases. This resulted in an overall loss of USD 153 The average price that the ETF previously sold SIGA share for is USD 6.64338 which is higher than the selling price of USD 6.38 on 2025-12-17. |
| TRDA - Entrada Therapeutics Inc | SELL | -350 @ USD 11.22 | USD -3,927 | The ETF sold 350 shares of TRDA on 2025-12-17. The shares were previously bought for an average price of USD 8.23347. The Entrada Therapeutics Inc shares were sold for 36.3% higher than average price of previous purchases. This sale made a profit of USD 1,045 The average price that the ETF previously sold TRDA share for is USD 8.45809 so the ETF has sold 350 shares on 2025-12-17 at a higher price than the previous selling average. |
| GLPG - Galapagos NV ADR | SELL | -130 @ USD 31.53 | USD -4,099 | The ETF sold 130 shares of GLPG on 2025-12-17. The shares were previously bought for an average price of USD 29.7426. The Galapagos NV ADR shares were sold for 6.0% higher than average price of previous purchases. This sale made a profit of USD 232 The average price that the ETF previously sold GLPG share for is USD 27.2955 so the ETF has sold 130 shares on 2025-12-17 at a higher price than the previous selling average. |
| GLPG - Galapagos N.V. | SELL | -130 @ USD 31.53 | USD -4,099 | The ETF sold 130 shares of GLPG on 2025-12-17. The shares were previously bought for an average price of USD 29.7426. The Galapagos N.V. shares were sold for 6.0% higher than average price of previous purchases. This sale made a profit of USD 232 The average price that the ETF previously sold GLPG share for is USD 27.2955 so the ETF has sold 130 shares on 2025-12-17 at a higher price than the previous selling average. |
| EOLS - Evolus Inc | SELL | -600 @ USD 7.08 | USD -4,248 | The ETF sold 600 shares of EOLS on 2025-12-17. The shares were previously bought for an average price of USD 8.56985. The Evolus Inc shares were sold for -17.4% lower than average price of previous purchases. This resulted in an overall loss of USD 894 The average price that the ETF previously sold EOLS share for is USD 10.7741 which is higher than the selling price of USD 7.08 on 2025-12-17. |
| PRTA - Prothena Corporation plc | SELL | -470 @ USD 9.42999 | USD -4,432 | The ETF sold 470 shares of PRTA on 2025-12-17. The shares were previously bought for an average price of USD 9.45542. The Prothena Corporation plc shares were sold for -0.3% lower than average price of previous purchases. This resulted in an overall loss of USD 12 The average price that the ETF previously sold PRTA share for is USD 12.3299 which is higher than the selling price of USD 9.42999 on 2025-12-17. |
| MRVI - Maravai Lifesciences Holdings Inc | SELL | -1,335 @ USD 3.46 | USD -4,619 | The ETF sold 1335 shares of MRVI on 2025-12-17. The shares were previously bought for an average price of USD 2.94024. The Maravai Lifesciences Holdings Inc shares were sold for 17.7% higher than average price of previous purchases. This sale made a profit of USD 694 The average price that the ETF previously sold MRVI share for is USD 3.70561 which is higher than the selling price of USD 3.46 on 2025-12-17. |
| CGEM - Cullinan Oncology LLC | SELL | -520 @ USD 9.59001 | USD -4,987 | The ETF sold 520 shares of CGEM on 2025-12-17. The shares were previously bought for an average price of USD 8.57694. The Cullinan Oncology LLC shares were sold for 11.8% higher than average price of previous purchases. This sale made a profit of USD 527 The average price that the ETF previously sold CGEM share for is USD 10.098 which is higher than the selling price of USD 9.59001 on 2025-12-17. |
| IRWD - Ironwood Pharmaceuticals Inc | SELL | -1,480 @ USD 3.37 | USD -4,988 | The ETF sold 1480 shares of IRWD on 2025-12-17. The shares were previously bought for an average price of USD 2.34928. The Ironwood Pharmaceuticals Inc shares were sold for 43.4% higher than average price of previous purchases. This sale made a profit of USD 1,511 The average price that the ETF previously sold IRWD share for is USD 2.68519 so the ETF has sold 1480 shares on 2025-12-17 at a higher price than the previous selling average. |
| LYEL - Lyell Immunopharma Inc | SELL | -160 @ USD 32.07 | USD -5,131 | The ETF sold 160 shares of LYEL on 2025-12-17. The shares were previously bought for an average price of USD 8.48496. The Lyell Immunopharma Inc shares were sold for 278.0% higher than average price of previous purchases. This sale made a profit of USD 3,774 The average price that the ETF previously sold LYEL share for is USD 6.65067 so the ETF has sold 160 shares on 2025-12-17 at a higher price than the previous selling average. |
| PACB - Pacific Biosciences of California | SELL | -2,695 @ USD 1.93 | USD -5,201 | The ETF sold 2695 shares of PACB on 2025-12-17. The shares were previously bought for an average price of USD 1.69829. The Pacific Biosciences of California shares were sold for 13.6% higher than average price of previous purchases. This sale made a profit of USD 624 The average price that the ETF previously sold PACB share for is USD 1.4531 so the ETF has sold 2695 shares on 2025-12-17 at a higher price than the previous selling average. |
| MGTX - MeiraGTx Holdings PLC | SELL | -680 @ USD 8.11001 | USD -5,515 | The ETF sold 680 shares of MGTX on 2025-12-17. The shares were previously bought for an average price of USD 7.4402. The MeiraGTx Holdings PLC shares were sold for 9.0% higher than average price of previous purchases. This sale made a profit of USD 455 The average price that the ETF previously sold MGTX share for is USD 6.97306 so the ETF has sold 680 shares on 2025-12-17 at a higher price than the previous selling average. |
| PRME - Prime Medicine, Inc. Common Stock | SELL | -1,485 @ USD 3.74 | USD -5,554 | The ETF sold 1485 shares of PRME on 2025-12-17. The shares were previously bought for an average price of USD 4.34727. The Prime Medicine, Inc. Common Stock shares were sold for -14.0% lower than average price of previous purchases. This resulted in an overall loss of USD 902 The average price that the ETF previously sold PRME share for is USD 2.79203 so the ETF has sold 1485 shares on 2025-12-17 at a higher price than the previous selling average. |
| RGNX - Regenxbio Inc | SELL | -445 @ USD 13.17 | USD -5,861 | The ETF sold 445 shares of RGNX on 2025-12-17. The shares were previously bought for an average price of USD 10.0406. The Regenxbio Inc shares were sold for 31.2% higher than average price of previous purchases. This sale made a profit of USD 1,393 The average price that the ETF previously sold RGNX share for is USD 7.90729 so the ETF has sold 445 shares on 2025-12-17 at a higher price than the previous selling average. |
| REPL - Replimune Group Inc | SELL | -675 @ USD 9.66 | USD -6,521 | The ETF sold 675 shares of REPL on 2025-12-17. The shares were previously bought for an average price of USD 9.15336. The Replimune Group Inc shares were sold for 5.5% higher than average price of previous purchases. This sale made a profit of USD 342 The average price that the ETF previously sold REPL share for is USD 9.95545 which is higher than the selling price of USD 9.66 on 2025-12-17. |
| KALV - Kalvista Pharmaceuticals Inc | SELL | -450 @ USD 14.85 | USD -6,683 | The ETF sold 450 shares of KALV on 2025-12-17. The shares were previously bought for an average price of USD 13.5733. The Kalvista Pharmaceuticals Inc shares were sold for 9.4% higher than average price of previous purchases. This sale made a profit of USD 575 The average price that the ETF previously sold KALV share for is USD 11.9422 so the ETF has sold 450 shares on 2025-12-17 at a higher price than the previous selling average. |
| PAHC - Phibro Animal Health Corporation | SELL | -165 @ USD 40.6 | USD -6,699 | The ETF sold 165 shares of PAHC on 2025-12-17. The shares were previously bought for an average price of USD 31.5119. The Phibro Animal Health Corporation shares were sold for 28.8% higher than average price of previous purchases. This sale made a profit of USD 1,500 The average price that the ETF previously sold PAHC share for is USD 25.8856 so the ETF has sold 165 shares on 2025-12-17 at a higher price than the previous selling average. |
| ORIC - Oric Pharmaceuticals Inc | SELL | -815 @ USD 8.22001 | USD -6,699 | The ETF sold 815 shares of ORIC on 2025-12-17. The shares were previously bought for an average price of USD 10.6475. The Oric Pharmaceuticals Inc shares were sold for -22.8% lower than average price of previous purchases. This resulted in an overall loss of USD 1,978 The average price that the ETF previously sold ORIC share for is USD 8.2964 which is higher than the selling price of USD 8.22001 on 2025-12-17. |
| ZLAB - Zai Lab Ltd | SELL | -400 @ USD 17.22 | USD -6,888 | The ETF sold 400 shares of ZLAB on 2025-12-17. The shares were previously bought for an average price of USD 31.0921. The Zai Lab Ltd shares were sold for -44.6% lower than average price of previous purchases. This resulted in an overall loss of USD 5,549 The average price that the ETF previously sold ZLAB share for is USD 30.9659 which is higher than the selling price of USD 17.22 on 2025-12-17. |
| JANX - Janux Therapeutics Inc | SELL | -505 @ USD 14.1 | USD -7,121 | The ETF sold 505 shares of JANX on 2025-12-17. The shares were previously bought for an average price of USD 26.2528. The Janux Therapeutics Inc shares were sold for -46.3% lower than average price of previous purchases. This resulted in an overall loss of USD 6,137 The average price that the ETF previously sold JANX share for is USD 36.1938 which is higher than the selling price of USD 14.1 on 2025-12-17. |
| VIR - Vir Biotechnology Inc | SELL | -1,160 @ USD 6.14 | USD -7,122 | The ETF sold 1160 shares of VIR on 2025-12-17. The shares were previously bought for an average price of USD 5.92884. The Vir Biotechnology Inc shares were sold for 3.6% higher than average price of previous purchases. This sale made a profit of USD 245 The average price that the ETF previously sold VIR share for is USD 6.36803 which is higher than the selling price of USD 6.14 on 2025-12-17. |
| VIR - Vidrala S.A | SELL | -1,160 @ USD 6.14 | USD -7,122 | The ETF sold 1160 shares of VIR on 2025-12-17. The shares were previously bought for an average price of USD 5.92884. The Vidrala S.A shares were sold for 3.6% higher than average price of previous purchases. This sale made a profit of USD 245 The average price that the ETF previously sold VIR share for is USD 6.36803 which is higher than the selling price of USD 6.14 on 2025-12-17. |
| GERN - Geron Corporation | SELL | -5,330 @ USD 1.4 | USD -7,462 | The ETF sold 5330 shares of GERN on 2025-12-17. The shares were previously bought for an average price of USD 1.43749. The Geron Corporation shares were sold for -2.6% lower than average price of previous purchases. This resulted in an overall loss of USD 200 The average price that the ETF previously sold GERN share for is USD 2.19575 which is higher than the selling price of USD 1.4 on 2025-12-17. |
| DAWN - Day One Biopharmaceuticals Inc | SELL | -855 @ USD 8.76 | USD -7,490 | The ETF sold 855 shares of DAWN on 2025-12-17. The shares were previously bought for an average price of USD 7.72272. The Day One Biopharmaceuticals Inc shares were sold for 13.4% higher than average price of previous purchases. This sale made a profit of USD 887 The average price that the ETF previously sold DAWN share for is USD 9.27776 which is higher than the selling price of USD 8.76 on 2025-12-17. |
| KROS - Keros Therapeutics Inc | SELL | -360 @ USD 20.83 | USD -7,499 | The ETF sold 360 shares of KROS on 2025-12-17. The shares were previously bought for an average price of USD 15.8434. The Keros Therapeutics Inc shares were sold for 31.5% higher than average price of previous purchases. This sale made a profit of USD 1,795 The average price that the ETF previously sold KROS share for is USD 19.8392 so the ETF has sold 360 shares on 2025-12-17 at a higher price than the previous selling average. |
| TBPH - Theravance Biopharma Inc | SELL | -420 @ USD 17.91 | USD -7,522 | The ETF sold 420 shares of TBPH on 2025-12-17. The shares were previously bought for an average price of USD 13.5517. The Theravance Biopharma Inc shares were sold for 32.2% higher than average price of previous purchases. This sale made a profit of USD 1,830 The average price that the ETF previously sold TBPH share for is USD 11.258 so the ETF has sold 420 shares on 2025-12-17 at a higher price than the previous selling average. |
| IOVA - Iovance Biotherapeutics Inc | SELL | -3,000 @ USD 2.52 | USD -7,560 | The ETF sold 3000 shares of IOVA on 2025-12-17. The shares were previously bought for an average price of USD 2.3941. The Iovance Biotherapeutics Inc shares were sold for 5.3% higher than average price of previous purchases. This sale made a profit of USD 378 The average price that the ETF previously sold IOVA share for is USD 4.92526 which is higher than the selling price of USD 2.52 on 2025-12-17. |
| ARVN - Arvinas Inc | SELL | -650 @ USD 11.72 | USD -7,618 | The ETF sold 650 shares of ARVN on 2025-12-17. The shares were previously bought for an average price of USD 9.94644. The Arvinas Inc shares were sold for 17.8% higher than average price of previous purchases. This sale made a profit of USD 1,153 The average price that the ETF previously sold ARVN share for is USD 12.3785 which is higher than the selling price of USD 11.72 on 2025-12-17. |
| ABUS - Arbutus Biopharma Corp | SELL | -1,645 @ USD 4.64 | USD -7,633 | The ETF sold 1645 shares of ABUS on 2025-12-17. The shares were previously bought for an average price of USD 3.83964. The Arbutus Biopharma Corp shares were sold for 20.8% higher than average price of previous purchases. This sale made a profit of USD 1,317 The average price that the ETF previously sold ABUS share for is USD 3.37963 so the ETF has sold 1645 shares on 2025-12-17 at a higher price than the previous selling average. |
| KURA - Kura Oncology Inc | SELL | -760 @ USD 10.18 | USD -7,737 | The ETF sold 760 shares of KURA on 2025-12-17. The shares were previously bought for an average price of USD 8.28389. The Kura Oncology Inc shares were sold for 22.9% higher than average price of previous purchases. This sale made a profit of USD 1,441 The average price that the ETF previously sold KURA share for is USD 8.88692 so the ETF has sold 760 shares on 2025-12-17 at a higher price than the previous selling average. |
| MNMD - Mind Medicine Inc | SELL | -650 @ USD 12.13 | USD -7,885 | The ETF sold 650 shares of MNMD on 2025-12-17. The shares were previously bought for an average price of USD 9.5334. The Mind Medicine Inc shares were sold for 27.2% higher than average price of previous purchases. This sale made a profit of USD 1,688 The average price that the ETF previously sold MNMD share for is USD 7.41572 so the ETF has sold 650 shares on 2025-12-17 at a higher price than the previous selling average. |
| ELVN - Enliven Therapeutics Inc. | SELL | -495 @ USD 16.02 | USD -7,930 | The ETF sold 495 shares of ELVN on 2025-12-17. The shares were previously bought for an average price of USD 20.5559. The Enliven Therapeutics Inc. shares were sold for -22.1% lower than average price of previous purchases. This resulted in an overall loss of USD 2,245 The average price that the ETF previously sold ELVN share for is USD 21.3306 which is higher than the selling price of USD 16.02 on 2025-12-17. |
| NTLA - Intellia Therapeutics Inc | SELL | -910 @ USD 8.79 | USD -7,999 | The ETF sold 910 shares of NTLA on 2025-12-17. The shares were previously bought for an average price of USD 11.4968. The Intellia Therapeutics Inc shares were sold for -23.5% lower than average price of previous purchases. This resulted in an overall loss of USD 2,463 The average price that the ETF previously sold NTLA share for is USD 11.1062 which is higher than the selling price of USD 8.79 on 2025-12-17. |
| TNGX - Tango Therapeutics Inc | SELL | -935 @ USD 8.78001 | USD -8,209 | The ETF sold 935 shares of TNGX on 2025-12-17. The shares were previously bought for an average price of USD 7.2819. The Tango Therapeutics Inc shares were sold for 20.6% higher than average price of previous purchases. This sale made a profit of USD 1,401 The average price that the ETF previously sold TNGX share for is USD 3.6927 so the ETF has sold 935 shares on 2025-12-17 at a higher price than the previous selling average. |
| ABCL - Abcellera Biologics Inc | SELL | -2,510 @ USD 3.35 | USD -8,409 | The ETF sold 2510 shares of ABCL on 2025-12-17. The shares were previously bought for an average price of USD 3.83934. The Abcellera Biologics Inc shares were sold for -12.7% lower than average price of previous purchases. This resulted in an overall loss of USD 1,228 The average price that the ETF previously sold ABCL share for is USD 3.19259 so the ETF has sold 2510 shares on 2025-12-17 at a higher price than the previous selling average. |
| SPRY - Silverback Therapeutics Inc | SELL | -870 @ USD 10.07 | USD -8,761 | The ETF sold 870 shares of SPRY on 2025-12-17. The shares were previously bought for an average price of USD 12.4193. The Silverback Therapeutics Inc shares were sold for -18.9% lower than average price of previous purchases. This resulted in an overall loss of USD 2,044 The average price that the ETF previously sold SPRY share for is USD 12.0382 which is higher than the selling price of USD 10.07 on 2025-12-17. |
| SVRA - Savara Inc | SELL | -1,445 @ USD 6.11 | USD -8,829 | The ETF sold 1445 shares of SVRA on 2025-12-17. The shares were previously bought for an average price of USD 3.7196. The Savara Inc shares were sold for 64.3% higher than average price of previous purchases. This sale made a profit of USD 3,454 The average price that the ETF previously sold SVRA share for is USD 2.95775 so the ETF has sold 1445 shares on 2025-12-17 at a higher price than the previous selling average. |
| AMLX - Amylyx Pharmaceuticals Inc | SELL | -745 @ USD 11.87 | USD -8,843 | The ETF sold 745 shares of AMLX on 2025-12-17. The shares were previously bought for an average price of USD 8.41455. The Amylyx Pharmaceuticals Inc shares were sold for 41.1% higher than average price of previous purchases. This sale made a profit of USD 2,574 The average price that the ETF previously sold AMLX share for is USD 7.93953 so the ETF has sold 745 shares on 2025-12-17 at a higher price than the previous selling average. |
| NVAX - Novavax Inc | SELL | -1,360 @ USD 6.53 | USD -8,881 | The ETF sold 1360 shares of NVAX on 2025-12-17. The shares were previously bought for an average price of USD 7.2023. The Novavax Inc shares were sold for -9.3% lower than average price of previous purchases. This resulted in an overall loss of USD 914 The average price that the ETF previously sold NVAX share for is USD 7.62802 which is higher than the selling price of USD 6.53 on 2025-12-17. |
| NVAX - Hana Microelectronics Public Company Limited | SELL | -1,360 @ USD 6.53 | USD -8,881 | The ETF sold 1360 shares of NVAX on 2025-12-17. The shares were previously bought for an average price of USD 7.2023. The Hana Microelectronics Public Company Limited shares were sold for -9.3% lower than average price of previous purchases. This resulted in an overall loss of USD 914 The average price that the ETF previously sold NVAX share for is USD 7.62802 which is higher than the selling price of USD 6.53 on 2025-12-17. |
| URGN - UroGen Pharma Ltd | SELL | -400 @ USD 22.62 | USD -9,048 | The ETF sold 400 shares of URGN on 2025-12-17. The shares were previously bought for an average price of USD 17.0229. The UroGen Pharma Ltd shares were sold for 32.9% higher than average price of previous purchases. This sale made a profit of USD 2,239 The average price that the ETF previously sold URGN share for is USD 13.1012 so the ETF has sold 400 shares on 2025-12-17 at a higher price than the previous selling average. |
| GRFS - Grifols SA ADR | SELL | -1,020 @ USD 8.91 | USD -9,088 | The ETF sold 1020 shares of GRFS on 2025-12-17. The shares were previously bought for an average price of USD 9.21387. The Grifols SA ADR shares were sold for -3.3% lower than average price of previous purchases. This resulted in an overall loss of USD 310 The average price that the ETF previously sold GRFS share for is USD 8.46064 so the ETF has sold 1020 shares on 2025-12-17 at a higher price than the previous selling average. |
| ERAS - Erasca Inc | SELL | -2,550 @ USD 3.64 | USD -9,282 | The ETF sold 2550 shares of ERAS on 2025-12-17. The shares were previously bought for an average price of USD 2.02691. The Erasca Inc shares were sold for 79.6% higher than average price of previous purchases. This sale made a profit of USD 4,113 The average price that the ETF previously sold ERAS share for is USD 2.0124 so the ETF has sold 2550 shares on 2025-12-17 at a higher price than the previous selling average. |
| PHAT - Phathom Pharmaceuticals Inc | SELL | -605 @ USD 15.36 | USD -9,293 | The ETF sold 605 shares of PHAT on 2025-12-17. The shares were previously bought for an average price of USD 10.5456. The Phathom Pharmaceuticals Inc shares were sold for 45.7% higher than average price of previous purchases. This sale made a profit of USD 2,913 The average price that the ETF previously sold PHAT share for is USD 7.79688 so the ETF has sold 605 shares on 2025-12-17 at a higher price than the previous selling average. |
| XNCR - Xencor Inc | SELL | -595 @ USD 15.8 | USD -9,401 | The ETF sold 595 shares of XNCR on 2025-12-17. The shares were previously bought for an average price of USD 12.5279. The Xencor Inc shares were sold for 26.1% higher than average price of previous purchases. This sale made a profit of USD 1,947 The average price that the ETF previously sold XNCR share for is USD 12.9516 so the ETF has sold 595 shares on 2025-12-17 at a higher price than the previous selling average. |
| CSTL - Castle Biosciences Inc | SELL | -240 @ USD 39.66 | USD -9,518 | The ETF sold 240 shares of CSTL on 2025-12-17. The shares were previously bought for an average price of USD 26.271. The Castle Biosciences Inc shares were sold for 51.0% higher than average price of previous purchases. This sale made a profit of USD 3,213 The average price that the ETF previously sold CSTL share for is USD 23.8541 so the ETF has sold 240 shares on 2025-12-17 at a higher price than the previous selling average. |
| XERS - Xeris Pharmaceuticals Inc | SELL | -1,395 @ USD 6.99 | USD -9,751 | The ETF sold 1395 shares of XERS on 2025-12-17. The shares were previously bought for an average price of USD 6.22689. The Xeris Pharmaceuticals Inc shares were sold for 12.3% higher than average price of previous purchases. This sale made a profit of USD 1,065 The average price that the ETF previously sold XERS share for is USD 4.81892 so the ETF has sold 1395 shares on 2025-12-17 at a higher price than the previous selling average. |
| PCRX - Pacira BioSciences, Inc. | SELL | -375 @ USD 26.55 | USD -9,956 | The ETF sold 375 shares of PCRX on 2025-12-17. The shares were previously bought for an average price of USD 23.8626. The Pacira BioSciences, Inc. shares were sold for 11.3% higher than average price of previous purchases. This sale made a profit of USD 1,008 The average price that the ETF previously sold PCRX share for is USD 22.0158 so the ETF has sold 375 shares on 2025-12-17 at a higher price than the previous selling average. |
| AMPH - Amphastar P | SELL | -385 @ USD 26.07 | USD -10,037 | The ETF sold 385 shares of AMPH on 2025-12-17. The shares were previously bought for an average price of USD 25.8292. The Amphastar P shares were sold for 0.9% higher than average price of previous purchases. This sale made a profit of USD 93 The average price that the ETF previously sold AMPH share for is USD 31.3819 which is higher than the selling price of USD 26.07 on 2025-12-17. |
| PGEN - Precigen Inc | SELL | -2,555 @ USD 3.98 | USD -10,169 | The ETF sold 2555 shares of PGEN on 2025-12-17. The shares were previously bought for an average price of USD 2.70172. The Precigen Inc shares were sold for 47.3% higher than average price of previous purchases. This sale made a profit of USD 3,266 The average price that the ETF previously sold PGEN share for is USD 1.74547 so the ETF has sold 2555 shares on 2025-12-17 at a higher price than the previous selling average. |
| ANAB - AnaptysBio Inc | SELL | -230 @ USD 45.69 | USD -10,509 | The ETF sold 230 shares of ANAB on 2025-12-17. The shares were previously bought for an average price of USD 28.5512. The AnaptysBio Inc shares were sold for 60.0% higher than average price of previous purchases. This sale made a profit of USD 3,942 The average price that the ETF previously sold ANAB share for is USD 19.4951 so the ETF has sold 230 shares on 2025-12-17 at a higher price than the previous selling average. |
| SANA - Sana Biotechnology Inc | SELL | -2,200 @ USD 4.78 | USD -10,516 | The ETF sold 2200 shares of SANA on 2025-12-17. The shares were previously bought for an average price of USD 3.49243. The Sana Biotechnology Inc shares were sold for 36.9% higher than average price of previous purchases. This sale made a profit of USD 2,833 The average price that the ETF previously sold SANA share for is USD 2.44573 so the ETF has sold 2200 shares on 2025-12-17 at a higher price than the previous selling average. |
| DVAX - Dynavax Technologies Corporation | SELL | -980 @ USD 10.79 | USD -10,574 | The ETF sold 980 shares of DVAX on 2025-12-17. The shares were previously bought for an average price of USD 10.6546. The Dynavax Technologies Corporation shares were sold for 1.3% higher than average price of previous purchases. This sale made a profit of USD 133 The average price that the ETF previously sold DVAX share for is USD 11.8845 which is higher than the selling price of USD 10.79 on 2025-12-17. |
| QURE - Uniqure NV | SELL | -460 @ USD 23.03 | USD -10,594 | The ETF sold 460 shares of QURE on 2025-12-17. The shares were previously bought for an average price of USD 23.4439. The Uniqure NV shares were sold for -1.8% lower than average price of previous purchases. This resulted in an overall loss of USD 190 The average price that the ETF previously sold QURE share for is USD 22.2066 so the ETF has sold 460 shares on 2025-12-17 at a higher price than the previous selling average. |
| INVA - Innoviva Inc | SELL | -545 @ USD 20.05 | USD -10,927 | The ETF sold 545 shares of INVA on 2025-12-17. The shares were previously bought for an average price of USD 19.6062. The Innoviva Inc shares were sold for 2.3% higher than average price of previous purchases. This sale made a profit of USD 242 The average price that the ETF previously sold INVA share for is USD 18.2044 so the ETF has sold 545 shares on 2025-12-17 at a higher price than the previous selling average. |
| GMAB - Genmab AS | SELL | -350 @ USD 31.71 | USD -11,099 | The ETF sold 350 shares of GMAB on 2025-12-17. The shares were previously bought for an average price of USD 25.5228. The Genmab AS shares were sold for 24.2% higher than average price of previous purchases. This sale made a profit of USD 2,166 The average price that the ETF previously sold GMAB share for is USD 22.8141 so the ETF has sold 350 shares on 2025-12-17 at a higher price than the previous selling average. |
| NVCR - Novocure Ltd | SELL | -930 @ USD 12.33 | USD -11,467 | The ETF sold 930 shares of NVCR on 2025-12-17. The shares were previously bought for an average price of USD 15.3912. The Novocure Ltd shares were sold for -19.9% lower than average price of previous purchases. This resulted in an overall loss of USD 2,847 The average price that the ETF previously sold NVCR share for is USD 19.5733 which is higher than the selling price of USD 12.33 on 2025-12-17. |
| RLAY - Relay Therapeutics Inc | SELL | -1,440 @ USD 8.03 | USD -11,563 | The ETF sold 1440 shares of RLAY on 2025-12-17. The shares were previously bought for an average price of USD 4.90988. The Relay Therapeutics Inc shares were sold for 63.5% higher than average price of previous purchases. This sale made a profit of USD 4,493 The average price that the ETF previously sold RLAY share for is USD 4.05133 so the ETF has sold 1440 shares on 2025-12-17 at a higher price than the previous selling average. |
| ARDX - Ardelyx Inc | SELL | -2,010 @ USD 5.79 | USD -11,638 | The ETF sold 2010 shares of ARDX on 2025-12-17. The shares were previously bought for an average price of USD 4.92786. The Ardelyx Inc shares were sold for 17.5% higher than average price of previous purchases. This sale made a profit of USD 1,733 The average price that the ETF previously sold ARDX share for is USD 5.22552 so the ETF has sold 2010 shares on 2025-12-17 at a higher price than the previous selling average. |
| IMCR - Immunocore Holdings Ltd | SELL | -340 @ USD 35.82 | USD -12,179 | The ETF sold 340 shares of IMCR on 2025-12-17. The shares were previously bought for an average price of USD 34.3094. The Immunocore Holdings Ltd shares were sold for 4.4% higher than average price of previous purchases. This sale made a profit of USD 514 The average price that the ETF previously sold IMCR share for is USD 30.8756 so the ETF has sold 340 shares on 2025-12-17 at a higher price than the previous selling average. |
| NRIX - Nurix Therapeutics Inc | SELL | -670 @ USD 18.21 | USD -12,201 | The ETF sold 670 shares of NRIX on 2025-12-17. The shares were previously bought for an average price of USD 13.2326. The Nurix Therapeutics Inc shares were sold for 37.6% higher than average price of previous purchases. This sale made a profit of USD 3,335 The average price that the ETF previously sold NRIX share for is USD 14.2814 so the ETF has sold 670 shares on 2025-12-17 at a higher price than the previous selling average. |
| FTRE - Fortrea Holdings Inc. | SELL | -755 @ USD 16.19 | USD -12,223 | The ETF sold 755 shares of FTRE on 2025-12-17. The shares were previously bought for an average price of USD 8.4198. The Fortrea Holdings Inc. shares were sold for 92.3% higher than average price of previous purchases. This sale made a profit of USD 5,867 The average price that the ETF previously sold FTRE share for is USD 12.7508 so the ETF has sold 755 shares on 2025-12-17 at a higher price than the previous selling average. |
| TSHA - Taysha Gene Therapies Inc | SELL | -2,275 @ USD 5.44 | USD -12,376 | The ETF sold 2275 shares of TSHA on 2025-12-17. The shares were previously bought for an average price of USD 3.26801. The Taysha Gene Therapies Inc shares were sold for 66.5% higher than average price of previous purchases. This sale made a profit of USD 4,941 The average price that the ETF previously sold TSHA share for is USD 2.13437 so the ETF has sold 2275 shares on 2025-12-17 at a higher price than the previous selling average. |
| COLL - Collegium Pharmaceutical Inc | SELL | -260 @ USD 48.9 | USD -12,714 | The ETF sold 260 shares of COLL on 2025-12-17. The shares were previously bought for an average price of USD 35.6563. The Collegium Pharmaceutical Inc shares were sold for 37.1% higher than average price of previous purchases. This sale made a profit of USD 3,443 The average price that the ETF previously sold COLL share for is USD 31.1589 so the ETF has sold 260 shares on 2025-12-17 at a higher price than the previous selling average. |
| AGIO - Agios Pharm | SELL | -500 @ USD 25.45 | USD -12,725 | The ETF sold 500 shares of AGIO on 2025-12-17. The shares were previously bought for an average price of USD 33.9293. The Agios Pharm shares were sold for -25.0% lower than average price of previous purchases. This resulted in an overall loss of USD 4,240 The average price that the ETF previously sold AGIO share for is USD 35.758 which is higher than the selling price of USD 25.45 on 2025-12-17. |
| BCRX - BioCryst Pharmaceuticals Inc | SELL | -1,815 @ USD 7.13 | USD -12,941 | The ETF sold 1815 shares of BCRX on 2025-12-17. The shares were previously bought for an average price of USD 8.03142. The BioCryst Pharmaceuticals Inc shares were sold for -11.2% lower than average price of previous purchases. This resulted in an overall loss of USD 1,636 The average price that the ETF previously sold BCRX share for is USD 7.5552 which is higher than the selling price of USD 7.13 on 2025-12-17. |
| HROW - Harrow Health Inc | SELL | -320 @ USD 44.39 | USD -14,205 | The ETF sold 320 shares of HROW on 2025-12-17. The shares were previously bought for an average price of USD 37.118. The Harrow Health Inc shares were sold for 19.6% higher than average price of previous purchases. This sale made a profit of USD 2,327 The average price that the ETF previously sold HROW share for is USD 33.4708 so the ETF has sold 320 shares on 2025-12-17 at a higher price than the previous selling average. |
| SNDX - Syndax Pharmaceuticals Inc | SELL | -740 @ USD 20.37 | USD -15,074 | The ETF sold 740 shares of SNDX on 2025-12-17. The shares were previously bought for an average price of USD 14.0596. The Syndax Pharmaceuticals Inc shares were sold for 44.9% higher than average price of previous purchases. This sale made a profit of USD 4,670 The average price that the ETF previously sold SNDX share for is USD 13.4628 so the ETF has sold 740 shares on 2025-12-17 at a higher price than the previous selling average. |
| LEGN - Legend Biotech Corp | SELL | -705 @ USD 21.42 | USD -15,101 | The ETF sold 705 shares of LEGN on 2025-12-17. The shares were previously bought for an average price of USD 32.7402. The Legend Biotech Corp shares were sold for -34.6% lower than average price of previous purchases. This resulted in an overall loss of USD 7,981 The average price that the ETF previously sold LEGN share for is USD 34.5102 which is higher than the selling price of USD 21.42 on 2025-12-17. |
| TXG - 10X Genomics Inc | SELL | -960 @ USD 15.75 | USD -15,120 | The ETF sold 960 shares of TXG on 2025-12-17. The shares were previously bought for an average price of USD 13.611. The 10X Genomics Inc shares were sold for 15.7% higher than average price of previous purchases. This sale made a profit of USD 2,053 The average price that the ETF previously sold TXG share for is USD 10.9067 so the ETF has sold 960 shares on 2025-12-17 at a higher price than the previous selling average. |
| TXG - Terex Corporation | SELL | -960 @ USD 15.75 | USD -15,120 | The ETF sold 960 shares of TXG on 2025-12-17. The shares were previously bought for an average price of USD 13.611. The Terex Corporation shares were sold for 15.7% higher than average price of previous purchases. This sale made a profit of USD 2,053 The average price that the ETF previously sold TXG share for is USD 10.9067 so the ETF has sold 960 shares on 2025-12-17 at a higher price than the previous selling average. |
| KNSA - Kiniksa Pharmaceuticals Ltd | SELL | -365 @ USD 41.47 | USD -15,137 | The ETF sold 365 shares of KNSA on 2025-12-17. The shares were previously bought for an average price of USD 32.8049. The Kiniksa Pharmaceuticals Ltd shares were sold for 26.4% higher than average price of previous purchases. This sale made a profit of USD 3,163 The average price that the ETF previously sold KNSA share for is USD 23.876 so the ETF has sold 365 shares on 2025-12-17 at a higher price than the previous selling average. |
| ANIP - ANI Pharmaceuticals Inc | SELL | -185 @ USD 82.35 | USD -15,235 | The ETF sold 185 shares of ANIP on 2025-12-17. The shares were previously bought for an average price of USD 74.884. The ANI Pharmaceuticals Inc shares were sold for 10.0% higher than average price of previous purchases. This sale made a profit of USD 1,381 The average price that the ETF previously sold ANIP share for is USD 68.4161 so the ETF has sold 185 shares on 2025-12-17 at a higher price than the previous selling average. |
| STOK - Stoke Therapeutics Inc | SELL | -465 @ USD 32.86 | USD -15,280 | The ETF sold 465 shares of STOK on 2025-12-17. The shares were previously bought for an average price of USD 19.6492. The Stoke Therapeutics Inc shares were sold for 67.2% higher than average price of previous purchases. This sale made a profit of USD 6,143 The average price that the ETF previously sold STOK share for is USD 12.3874 so the ETF has sold 465 shares on 2025-12-17 at a higher price than the previous selling average. |
| MNKD - MannKind Corp | SELL | -2,645 @ USD 5.97 | USD -15,791 | The ETF sold 2645 shares of MNKD on 2025-12-17. The shares were previously bought for an average price of USD 4.95458. The MannKind Corp shares were sold for 20.5% higher than average price of previous purchases. This sale made a profit of USD 2,686 The average price that the ETF previously sold MNKD share for is USD 5.54445 so the ETF has sold 2645 shares on 2025-12-17 at a higher price than the previous selling average. |
| VCEL - Vericel Corp Ord | SELL | -435 @ USD 36.4 | USD -15,834 | The ETF sold 435 shares of VCEL on 2025-12-17. The shares were previously bought for an average price of USD 39.9007. The Vericel Corp Ord shares were sold for -8.8% lower than average price of previous purchases. This resulted in an overall loss of USD 1,523 The average price that the ETF previously sold VCEL share for is USD 44.7327 which is higher than the selling price of USD 36.4 on 2025-12-17. |
| ZYME - Zymeworks Inc. Common Stock | SELL | -640 @ USD 25.59 | USD -16,378 | The ETF sold 640 shares of ZYME on 2025-12-17. The shares were previously bought for an average price of USD 17.3812. The Zymeworks Inc. Common Stock shares were sold for 47.2% higher than average price of previous purchases. This sale made a profit of USD 5,254 The average price that the ETF previously sold ZYME share for is USD 14.0896 so the ETF has sold 640 shares on 2025-12-17 at a higher price than the previous selling average. |
| TWST - Twist Bioscience Corp | SELL | -520 @ USD 32.13 | USD -16,708 | The ETF sold 520 shares of TWST on 2025-12-17. The shares were previously bought for an average price of USD 34.6802. The Twist Bioscience Corp shares were sold for -7.4% lower than average price of previous purchases. This resulted in an overall loss of USD 1,326 The average price that the ETF previously sold TWST share for is USD 38.2287 which is higher than the selling price of USD 32.13 on 2025-12-17. |
| IBRX - Immunitybio Inc | SELL | -7,970 @ USD 2.11 | USD -16,817 | The ETF sold 7970 shares of IBRX on 2025-12-17. The shares were previously bought for an average price of USD 2.6304. The Immunitybio Inc shares were sold for -19.8% lower than average price of previous purchases. This resulted in an overall loss of USD 4,148 The average price that the ETF previously sold IBRX share for is USD 2.99557 which is higher than the selling price of USD 2.11 on 2025-12-17. |
| RXRX - Recursion Pharmaceuticals Inc | SELL | -3,620 @ USD 4.68 | USD -16,942 | The ETF sold 3620 shares of RXRX on 2025-12-17. The shares were previously bought for an average price of USD 5.51461. The Recursion Pharmaceuticals Inc shares were sold for -15.1% lower than average price of previous purchases. This resulted in an overall loss of USD 3,021 The average price that the ETF previously sold RXRX share for is USD 5.47145 which is higher than the selling price of USD 4.68 on 2025-12-17. |
| SYRE - Spyre Therapeutics Inc. | SELL | -515 @ USD 33.06 | USD -17,026 | The ETF sold 515 shares of SYRE on 2025-12-17. The shares were previously bought for an average price of USD 21.6111. The Spyre Therapeutics Inc. shares were sold for 53.0% higher than average price of previous purchases. This sale made a profit of USD 5,896 The average price that the ETF previously sold SYRE share for is USD 17.008 so the ETF has sold 515 shares on 2025-12-17 at a higher price than the previous selling average. |
| AVDL - Avadel Pharmaceuticals PLC | SELL | -805 @ USD 21.4 | USD -17,227 | The ETF sold 805 shares of AVDL on 2025-12-17. The shares were previously bought for an average price of USD 13.7243. The Avadel Pharmaceuticals PLC shares were sold for 55.9% higher than average price of previous purchases. This sale made a profit of USD 6,179 The average price that the ETF previously sold AVDL share for is USD 11.3807 so the ETF has sold 805 shares on 2025-12-17 at a higher price than the previous selling average. |
| SRPT - Sarepta Therapeutics Inc | SELL | -830 @ USD 21.14 | USD -17,546 | The ETF sold 830 shares of SRPT on 2025-12-17. The shares were previously bought for an average price of USD 30.0903. The Sarepta Therapeutics Inc shares were sold for -29.7% lower than average price of previous purchases. This resulted in an overall loss of USD 7,429 The average price that the ETF previously sold SRPT share for is USD 73.8324 which is higher than the selling price of USD 21.14 on 2025-12-17. |
| AUPH - Aurinia Pharmaceuticals Inc | SELL | -1,130 @ USD 15.79 | USD -17,843 | The ETF sold 1130 shares of AUPH on 2025-12-17. The shares were previously bought for an average price of USD 11.3392. The Aurinia Pharmaceuticals Inc shares were sold for 39.3% higher than average price of previous purchases. This sale made a profit of USD 5,029 The average price that the ETF previously sold AUPH share for is USD 9.64219 so the ETF has sold 1130 shares on 2025-12-17 at a higher price than the previous selling average. |
| OLMA - Olema Pharmaceuticals Inc | SELL | -580 @ USD 32.6 | USD -18,908 | The ETF sold 580 shares of OLMA on 2025-12-17. The shares were previously bought for an average price of USD 11.1658. The Olema Pharmaceuticals Inc shares were sold for 192.0% higher than average price of previous purchases. This sale made a profit of USD 12,432 The average price that the ETF previously sold OLMA share for is USD 7.05934 so the ETF has sold 580 shares on 2025-12-17 at a higher price than the previous selling average. |
| HRMY - Harmony Biosciences Holdings | SELL | -490 @ USD 38.78 | USD -19,002 | The ETF sold 490 shares of HRMY on 2025-12-17. The shares were previously bought for an average price of USD 33.4492. The Harmony Biosciences Holdings shares were sold for 15.9% higher than average price of previous purchases. This sale made a profit of USD 2,612 The average price that the ETF previously sold HRMY share for is USD 32.1123 so the ETF has sold 490 shares on 2025-12-17 at a higher price than the previous selling average. |
| EWTX - Edgewise Therapeutics Inc | SELL | -895 @ USD 22.31 | USD -19,967 | The ETF sold 895 shares of EWTX on 2025-12-17. The shares were previously bought for an average price of USD 17.9438. The Edgewise Therapeutics Inc shares were sold for 24.3% higher than average price of previous purchases. This sale made a profit of USD 3,908 The average price that the ETF previously sold EWTX share for is USD 21.8959 so the ETF has sold 895 shares on 2025-12-17 at a higher price than the previous selling average. |
| OCUL - Ocular Therapeutix Inc | SELL | -1,480 @ USD 13.72 | USD -20,306 | The ETF sold 1480 shares of OCUL on 2025-12-17. The shares were previously bought for an average price of USD 10.7426. The Ocular Therapeutix Inc shares were sold for 27.7% higher than average price of previous purchases. This sale made a profit of USD 4,407 The average price that the ETF previously sold OCUL share for is USD 8.74764 so the ETF has sold 1480 shares on 2025-12-17 at a higher price than the previous selling average. |
| CNTA - Centessa Pharmaceuticals PLC ADR | SELL | -815 @ USD 24.98 | USD -20,359 | The ETF sold 815 shares of CNTA on 2025-12-17. The shares were previously bought for an average price of USD 19.5396. The Centessa Pharmaceuticals PLC ADR shares were sold for 27.8% higher than average price of previous purchases. This sale made a profit of USD 4,434 The average price that the ETF previously sold CNTA share for is USD 17.3907 so the ETF has sold 815 shares on 2025-12-17 at a higher price than the previous selling average. |
| ADPT - Adaptive Biotechnologies Corp | SELL | -1,295 @ USD 16.12 | USD -20,875 | The ETF sold 1295 shares of ADPT on 2025-12-17. The shares were previously bought for an average price of USD 13.4506. The Adaptive Biotechnologies Corp shares were sold for 19.8% higher than average price of previous purchases. This sale made a profit of USD 3,457 The average price that the ETF previously sold ADPT share for is USD 8.21023 so the ETF has sold 1295 shares on 2025-12-17 at a higher price than the previous selling average. |
| MLYS - Mineralys Therapeutics, Inc. Common Stock | SELL | -565 @ USD 37.02 | USD -20,916 | The ETF sold 565 shares of MLYS on 2025-12-17. The shares were previously bought for an average price of USD 24.5678. The Mineralys Therapeutics, Inc. Common Stock shares were sold for 50.7% higher than average price of previous purchases. This sale made a profit of USD 7,035 The average price that the ETF previously sold MLYS share for is USD 17.7474 so the ETF has sold 565 shares on 2025-12-17 at a higher price than the previous selling average. |
| DNLI - Denali Therapeutics Inc | SELL | -1,245 @ USD 16.81 | USD -20,928 | The ETF sold 1245 shares of DNLI on 2025-12-17. The shares were previously bought for an average price of USD 16.1568. The Denali Therapeutics Inc shares were sold for 4.0% higher than average price of previous purchases. This sale made a profit of USD 813 The average price that the ETF previously sold DNLI share for is USD 17.2813 which is higher than the selling price of USD 16.81 on 2025-12-17. |
| BEAM - Beam Therapeutics Inc | SELL | -860 @ USD 25.6 | USD -22,016 | The ETF sold 860 shares of BEAM on 2025-12-17. The shares were previously bought for an average price of USD 21.9707. The Beam Therapeutics Inc shares were sold for 16.5% higher than average price of previous purchases. This sale made a profit of USD 3,121 The average price that the ETF previously sold BEAM share for is USD 22.6764 so the ETF has sold 860 shares on 2025-12-17 at a higher price than the previous selling average. |
| WVE - Wave Life Sciences Ltd | SELL | -1,355 @ USD 16.34 | USD -22,141 | The ETF sold 1355 shares of WVE on 2025-12-17. The shares were previously bought for an average price of USD 8.32371. The Wave Life Sciences Ltd shares were sold for 96.3% higher than average price of previous purchases. This sale made a profit of USD 10,862 The average price that the ETF previously sold WVE share for is USD 8.67291 so the ETF has sold 1355 shares on 2025-12-17 at a higher price than the previous selling average. |
| DYN - Dyne Therapeutics Inc | SELL | -1,195 @ USD 18.9 | USD -22,586 | The ETF sold 1195 shares of DYN on 2025-12-17. The shares were previously bought for an average price of USD 14.4536. The Dyne Therapeutics Inc shares were sold for 30.8% higher than average price of previous purchases. This sale made a profit of USD 5,313 The average price that the ETF previously sold DYN share for is USD 17.2786 so the ETF has sold 1195 shares on 2025-12-17 at a higher price than the previous selling average. |
| DYN - DYNAGREEN EN.PR.GR.H YC 1 | SELL | -1,195 @ USD 18.9 | USD -22,586 | The ETF sold 1195 shares of DYN on 2025-12-17. The shares were previously bought for an average price of USD 14.4536. The DYNAGREEN EN.PR.GR.H YC 1 shares were sold for 30.8% higher than average price of previous purchases. This sale made a profit of USD 5,313 The average price that the ETF previously sold DYN share for is USD 17.2786 so the ETF has sold 1195 shares on 2025-12-17 at a higher price than the previous selling average. |
| SUPN - Supernus Pharmaceuticals Inc | SELL | -470 @ USD 48.75 | USD -22,913 | The ETF sold 470 shares of SUPN on 2025-12-17. The shares were previously bought for an average price of USD 39.4199. The Supernus Pharmaceuticals Inc shares were sold for 23.7% higher than average price of previous purchases. This sale made a profit of USD 4,385 The average price that the ETF previously sold SUPN share for is USD 37.1883 so the ETF has sold 470 shares on 2025-12-17 at a higher price than the previous selling average. |
| CGON - CG Oncology, Inc. Common stock | SELL | -640 @ USD 37.37 | USD -23,917 | The ETF sold 640 shares of CGON on 2025-12-17. The shares were previously bought for an average price of USD 33.0567. The CG Oncology, Inc. Common stock shares were sold for 13.0% higher than average price of previous purchases. This sale made a profit of USD 2,761 The average price that the ETF previously sold CGON share for is USD 28.629 so the ETF has sold 640 shares on 2025-12-17 at a higher price than the previous selling average. |
| IDYA - Ideaya Biosciences Inc | SELL | -740 @ USD 33.73 | USD -24,960 | The ETF sold 740 shares of IDYA on 2025-12-17. The shares were previously bought for an average price of USD 26.2583. The Ideaya Biosciences Inc shares were sold for 28.5% higher than average price of previous purchases. This sale made a profit of USD 5,529 The average price that the ETF previously sold IDYA share for is USD 23.0886 so the ETF has sold 740 shares on 2025-12-17 at a higher price than the previous selling average. |
| IRON - Ironveld Plc | SELL | -290 @ USD 87.49 | USD -25,372 | The ETF sold 290 shares of IRON on 2025-12-17. The shares were previously bought for an average price of USD 66.217. The Ironveld Plc shares were sold for 32.1% higher than average price of previous purchases. This sale made a profit of USD 6,169 The average price that the ETF previously sold IRON share for is USD 57.9177 so the ETF has sold 290 shares on 2025-12-17 at a higher price than the previous selling average. |
| TVTX - Travere Therapeutics Inc | SELL | -755 @ USD 33.89 | USD -25,587 | The ETF sold 755 shares of TVTX on 2025-12-17. The shares were previously bought for an average price of USD 24.1834. The Travere Therapeutics Inc shares were sold for 40.1% higher than average price of previous purchases. This sale made a profit of USD 7,328 The average price that the ETF previously sold TVTX share for is USD 19.8181 so the ETF has sold 755 shares on 2025-12-17 at a higher price than the previous selling average. |
| GRAL - GRAIL, LLC | SELL | -300 @ USD 85.87 | USD -25,761 | The ETF sold 300 shares of GRAL on 2025-12-17. The shares were previously bought for an average price of USD 63.9902. The GRAIL, LLC shares were sold for 34.2% higher than average price of previous purchases. This sale made a profit of USD 6,564 The average price that the ETF previously sold GRAL share for is USD 34.6786 so the ETF has sold 300 shares on 2025-12-17 at a higher price than the previous selling average. |
| VERA - Vera Therapeutics Inc | SELL | -540 @ USD 48.53 | USD -26,206 | The ETF sold 540 shares of VERA on 2025-12-17. The shares were previously bought for an average price of USD 30.2541. The Vera Therapeutics Inc shares were sold for 60.4% higher than average price of previous purchases. This sale made a profit of USD 9,869 The average price that the ETF previously sold VERA share for is USD 28.7467 so the ETF has sold 540 shares on 2025-12-17 at a higher price than the previous selling average. |
| APLS - Apellis Pharmaceuticals Inc | SELL | -1,060 @ USD 25.2 | USD -26,712 | The ETF sold 1060 shares of APLS on 2025-12-17. The shares were previously bought for an average price of USD 21.1068. The Apellis Pharmaceuticals Inc shares were sold for 19.4% higher than average price of previous purchases. This sale made a profit of USD 4,339 The average price that the ETF previously sold APLS share for is USD 24.9501 so the ETF has sold 1060 shares on 2025-12-17 at a higher price than the previous selling average. |
| RARE - Ultragenyx | SELL | -810 @ USD 33.21 | USD -26,900 | The ETF sold 810 shares of RARE on 2025-12-17. The shares were previously bought for an average price of USD 35.8581. The Ultragenyx shares were sold for -7.4% lower than average price of previous purchases. This resulted in an overall loss of USD 2,145 The average price that the ETF previously sold RARE share for is USD 37.1631 which is higher than the selling price of USD 33.21 on 2025-12-17. |
| RARE - WISETFWTMRARETFP | SELL | -810 @ USD 33.21 | USD -26,900 | The ETF sold 810 shares of RARE on 2025-12-17. The shares were previously bought for an average price of USD 35.8581. The WISETFWTMRARETFP shares were sold for -7.4% lower than average price of previous purchases. This resulted in an overall loss of USD 2,145 The average price that the ETF previously sold RARE share for is USD 37.1631 which is higher than the selling price of USD 33.21 on 2025-12-17. |
| TARS - Tarsus Pharmaceuticals Inc | SELL | -355 @ USD 77.77 | USD -27,608 | The ETF sold 355 shares of TARS on 2025-12-17. The shares were previously bought for an average price of USD 56.6878. The Tarsus Pharmaceuticals Inc shares were sold for 37.2% higher than average price of previous purchases. This sale made a profit of USD 7,484 The average price that the ETF previously sold TARS share for is USD 51.1188 so the ETF has sold 355 shares on 2025-12-17 at a higher price than the previous selling average. |
| XENE - Xenon Pharmaceuticals Inc | SELL | -645 @ USD 43.01 | USD -27,741 | The ETF sold 645 shares of XENE on 2025-12-17. The shares were previously bought for an average price of USD 37.5806. The Xenon Pharmaceuticals Inc shares were sold for 14.4% higher than average price of previous purchases. This sale made a profit of USD 3,502 The average price that the ETF previously sold XENE share for is USD 36.3915 so the ETF has sold 645 shares on 2025-12-17 at a higher price than the previous selling average. |
| VCYT - Veracyte Inc | SELL | -660 @ USD 42.21 | USD -27,859 | The ETF sold 660 shares of VCYT on 2025-12-17. The shares were previously bought for an average price of USD 34.9468. The Veracyte Inc shares were sold for 20.8% higher than average price of previous purchases. This sale made a profit of USD 4,794 The average price that the ETF previously sold VCYT share for is USD 34.2142 so the ETF has sold 660 shares on 2025-12-17 at a higher price than the previous selling average. |
| ARQT - Arcutis Biotherapeutics Inc | SELL | -1,010 @ USD 28.34 | USD -28,623 | The ETF sold 1010 shares of ARQT on 2025-12-17. The shares were previously bought for an average price of USD 20.1616. The Arcutis Biotherapeutics Inc shares were sold for 40.6% higher than average price of previous purchases. This sale made a profit of USD 8,260 The average price that the ETF previously sold ARQT share for is USD 14.808 so the ETF has sold 1010 shares on 2025-12-17 at a higher price than the previous selling average. |
| FOLD - Amicus Therapeutics Inc | SELL | -2,615 @ USD 11 | USD -28,765 | The ETF sold 2615 shares of FOLD on 2025-12-17. The shares were previously bought for an average price of USD 8.09081. The Amicus Therapeutics Inc shares were sold for 36.0% higher than average price of previous purchases. This sale made a profit of USD 7,608 The average price that the ETF previously sold FOLD share for is USD 8.54888 so the ETF has sold 2615 shares on 2025-12-17 at a higher price than the previous selling average. |
| MIRM - Mirum Pharmaceuticals Inc | SELL | -420 @ USD 69 | USD -28,980 | The ETF sold 420 shares of MIRM on 2025-12-17. The shares were previously bought for an average price of USD 59.3746. The Mirum Pharmaceuticals Inc shares were sold for 16.2% higher than average price of previous purchases. This sale made a profit of USD 4,043 The average price that the ETF previously sold MIRM share for is USD 49.7909 so the ETF has sold 420 shares on 2025-12-17 at a higher price than the previous selling average. |
| APGE - Apogee Therapeutics, Inc. Common Stock | SELL | -390 @ USD 75.5 | USD -29,445 | The ETF sold 390 shares of APGE on 2025-12-17. The shares were previously bought for an average price of USD 52.0132. The Apogee Therapeutics, Inc. Common Stock shares were sold for 45.2% higher than average price of previous purchases. This sale made a profit of USD 9,160 The average price that the ETF previously sold APGE share for is USD 41.7917 so the ETF has sold 390 shares on 2025-12-17 at a higher price than the previous selling average. |
| GPCR - Structure Therapeutics Inc. American Depositary Shares | SELL | -500 @ USD 59.97 | USD -29,985 | The ETF sold 500 shares of GPCR on 2025-12-17. The shares were previously bought for an average price of USD 27.9063. The Structure Therapeutics Inc. American Depositary Shares shares were sold for 114.9% higher than average price of previous purchases. This sale made a profit of USD 16,032 The average price that the ETF previously sold GPCR share for is USD 24.5561 so the ETF has sold 500 shares on 2025-12-17 at a higher price than the previous selling average. |
| ACLX - Arcellx Inc | SELL | -470 @ USD 64.72 | USD -30,418 | The ETF sold 470 shares of ACLX on 2025-12-17. The shares were previously bought for an average price of USD 72.202. The Arcellx Inc shares were sold for -10.4% lower than average price of previous purchases. This resulted in an overall loss of USD 3,517 The average price that the ETF previously sold ACLX share for is USD 75.3414 which is higher than the selling price of USD 64.72 on 2025-12-17. |
| TERN - Tern Plc | SELL | -740 @ USD 41.98 | USD -31,065 | The ETF sold 740 shares of TERN on 2025-12-17. The shares were previously bought for an average price of USD 11.663. The Tern Plc shares were sold for 259.9% higher than average price of previous purchases. This sale made a profit of USD 22,435 The average price that the ETF previously sold TERN share for is USD 6.49629 so the ETF has sold 740 shares on 2025-12-17 at a higher price than the previous selling average. |
| LGND - Ligand Pharmaceuticals Incorporated | SELL | -165 @ USD 194.59 | USD -32,107 | The ETF sold 165 shares of LGND on 2025-12-17. The shares were previously bought for an average price of USD 149.15. The Ligand Pharmaceuticals Incorporated shares were sold for 30.5% higher than average price of previous purchases. This sale made a profit of USD 7,498 The average price that the ETF previously sold LGND share for is USD 124.581 so the ETF has sold 165 shares on 2025-12-17 at a higher price than the previous selling average. |
| AMRX - Amneal Pharmaceuticals, Inc. Class A Common Stock | SELL | -2,640 @ USD 12.33 | USD -32,551 | The ETF sold 2640 shares of AMRX on 2025-12-17. The shares were previously bought for an average price of USD 9.64518. The Amneal Pharmaceuticals, Inc. Class A Common Stock shares were sold for 27.8% higher than average price of previous purchases. This sale made a profit of USD 7,088 The average price that the ETF previously sold AMRX share for is USD 8.88397 so the ETF has sold 2640 shares on 2025-12-17 at a higher price than the previous selling average. |
| SRRK - Scholar Rock Holding Corp | SELL | -805 @ USD 44.01 | USD -35,428 | The ETF sold 805 shares of SRRK on 2025-12-17. The shares were previously bought for an average price of USD 36.9163. The Scholar Rock Holding Corp shares were sold for 19.2% higher than average price of previous purchases. This sale made a profit of USD 5,710 The average price that the ETF previously sold SRRK share for is USD 32.2057 so the ETF has sold 805 shares on 2025-12-17 at a higher price than the previous selling average. |
| ADMA - ADMA Biologics Inc | SELL | -2,000 @ USD 18.83 | USD -37,660 | The ETF sold 2000 shares of ADMA on 2025-12-17. The shares were previously bought for an average price of USD 17.8309. The ADMA Biologics Inc shares were sold for 5.6% higher than average price of previous purchases. This sale made a profit of USD 1,998 The average price that the ETF previously sold ADMA share for is USD 17.748 so the ETF has sold 2000 shares on 2025-12-17 at a higher price than the previous selling average. |
| CRNX - Crinetics Pharmaceuticals Inc | SELL | -795 @ USD 47.69 | USD -37,914 | The ETF sold 795 shares of CRNX on 2025-12-17. The shares were previously bought for an average price of USD 37.9409. The Crinetics Pharmaceuticals Inc shares were sold for 25.7% higher than average price of previous purchases. This sale made a profit of USD 7,751 The average price that the ETF previously sold CRNX share for is USD 36.7404 so the ETF has sold 795 shares on 2025-12-17 at a higher price than the previous selling average. |
| ACAD - ACADIA Pharmaceuticals Inc | SELL | -1,415 @ USD 26.93 | USD -38,106 | The ETF sold 1415 shares of ACAD on 2025-12-17. The shares were previously bought for an average price of USD 22.0973. The ACADIA Pharmaceuticals Inc shares were sold for 21.9% higher than average price of previous purchases. This sale made a profit of USD 6,838 The average price that the ETF previously sold ACAD share for is USD 18.3087 so the ETF has sold 1415 shares on 2025-12-17 at a higher price than the previous selling average. |
| ALKS - Alkermes Plc | SELL | -1,395 @ USD 28.04 | USD -39,116 | The ETF sold 1395 shares of ALKS on 2025-12-17. The shares were previously bought for an average price of USD 30.05. The Alkermes Plc shares were sold for -6.7% lower than average price of previous purchases. This resulted in an overall loss of USD 2,804 The average price that the ETF previously sold ALKS share for is USD 29.4504 which is higher than the selling price of USD 28.04 on 2025-12-17. |
| IMVT - Immunovant Inc | SELL | -1,465 @ USD 26.98 | USD -39,526 | The ETF sold 1465 shares of IMVT on 2025-12-17. The shares were previously bought for an average price of USD 19.1832. The Immunovant Inc shares were sold for 40.6% higher than average price of previous purchases. This sale made a profit of USD 11,422 The average price that the ETF previously sold IMVT share for is USD 20.12 so the ETF has sold 1465 shares on 2025-12-17 at a higher price than the previous selling average. |
| CRSP - Crispr Therapeutics AG | SELL | -765 @ USD 54.74 | USD -41,876 | The ETF sold 765 shares of CRSP on 2025-12-17. The shares were previously bought for an average price of USD 53.3058. The Crispr Therapeutics AG shares were sold for 2.7% higher than average price of previous purchases. This sale made a profit of USD 1,097 The average price that the ETF previously sold CRSP share for is USD 43.6464 so the ETF has sold 765 shares on 2025-12-17 at a higher price than the previous selling average. |
| PRAX - Praxis Precision Medicines Inc | SELL | -175 @ USD 265.86 | USD -46,526 | The ETF sold 175 shares of PRAX on 2025-12-17. The shares were previously bought for an average price of USD 98.2598. The Praxis Precision Medicines Inc shares were sold for 170.6% higher than average price of previous purchases. This sale made a profit of USD 29,330 The average price that the ETF previously sold PRAX share for is USD 62.4602 so the ETF has sold 175 shares on 2025-12-17 at a higher price than the previous selling average. |
| COGT - Cogent Biosciences Inc | SELL | -1,180 @ USD 39.45 | USD -46,551 | The ETF sold 1180 shares of COGT on 2025-12-17. The shares were previously bought for an average price of USD 18.29. The Cogent Biosciences Inc shares were sold for 115.7% higher than average price of previous purchases. This sale made a profit of USD 24,969 The average price that the ETF previously sold COGT share for is USD 9.68865 so the ETF has sold 1180 shares on 2025-12-17 at a higher price than the previous selling average. |
| PTGX - Protagonist Therapeutics Inc | SELL | -525 @ USD 89.34 | USD -46,904 | The ETF sold 525 shares of PTGX on 2025-12-17. The shares were previously bought for an average price of USD 64.886. The Protagonist Therapeutics Inc shares were sold for 37.7% higher than average price of previous purchases. This sale made a profit of USD 12,838 The average price that the ETF previously sold PTGX share for is USD 50.5068 so the ETF has sold 525 shares on 2025-12-17 at a higher price than the previous selling average. |
| PCVX - Vaxcyte Inc | SELL | -1,095 @ USD 43.06 | USD -47,151 | The ETF sold 1095 shares of PCVX on 2025-12-17. The shares were previously bought for an average price of USD 45.0066. The Vaxcyte Inc shares were sold for -4.3% lower than average price of previous purchases. This resulted in an overall loss of USD 2,132 The average price that the ETF previously sold PCVX share for is USD 52.3184 which is higher than the selling price of USD 43.06 on 2025-12-17. |
| KYMR - Kymera Therapeutics Inc | SELL | -600 @ USD 82.07 | USD -49,242 | The ETF sold 600 shares of KYMR on 2025-12-17. The shares were previously bought for an average price of USD 52.5563. The Kymera Therapeutics Inc shares were sold for 56.2% higher than average price of previous purchases. This sale made a profit of USD 17,708 The average price that the ETF previously sold KYMR share for is USD 39.1713 so the ETF has sold 600 shares on 2025-12-17 at a higher price than the previous selling average. |
| PTCT - PTC Therapeutics Inc | SELL | -670 @ USD 74.94 | USD -50,210 | The ETF sold 670 shares of PTCT on 2025-12-17. The shares were previously bought for an average price of USD 61.273. The PTC Therapeutics Inc shares were sold for 22.3% higher than average price of previous purchases. This sale made a profit of USD 9,157 The average price that the ETF previously sold PTCT share for is USD 49.8456 so the ETF has sold 670 shares on 2025-12-17 at a higher price than the previous selling average. |
| NUVL - Nuvalent Inc | SELL | -560 @ USD 101.25 | USD -56,700 | The ETF sold 560 shares of NUVL on 2025-12-17. The shares were previously bought for an average price of USD 88.7259. The Nuvalent Inc shares were sold for 14.1% higher than average price of previous purchases. This sale made a profit of USD 7,013 The average price that the ETF previously sold NUVL share for is USD 79.4291 so the ETF has sold 560 shares on 2025-12-17 at a higher price than the previous selling average. |
| KRYS - Krystal Biotech Inc | SELL | -245 @ USD 235.8 | USD -57,771 | The ETF sold 245 shares of KRYS on 2025-12-17. The shares were previously bought for an average price of USD 177.51. The Krystal Biotech Inc shares were sold for 32.8% higher than average price of previous purchases. This sale made a profit of USD 14,281 The average price that the ETF previously sold KRYS share for is USD 167.506 so the ETF has sold 245 shares on 2025-12-17 at a higher price than the previous selling average. |
| CYTK - Cytokinetics Inc | SELL | -1,000 @ USD 59.82 | USD -59,820 | The ETF sold 1000 shares of CYTK on 2025-12-17. The shares were previously bought for an average price of USD 48.9512. The Cytokinetics Inc shares were sold for 22.2% higher than average price of previous purchases. This sale made a profit of USD 10,869 The average price that the ETF previously sold CYTK share for is USD 45.9277 so the ETF has sold 1000 shares on 2025-12-17 at a higher price than the previous selling average. |
| AXSM - Axsome Therapeutics Inc | SELL | -420 @ USD 148 | USD -62,160 | The ETF sold 420 shares of AXSM on 2025-12-17. The shares were previously bought for an average price of USD 123.568. The Axsome Therapeutics Inc shares were sold for 19.8% higher than average price of previous purchases. This sale made a profit of USD 10,261 The average price that the ETF previously sold AXSM share for is USD 104.826 so the ETF has sold 420 shares on 2025-12-17 at a higher price than the previous selling average. |
| RYTM - Rhythm Pharmaceuticals Inc | SELL | -560 @ USD 111.86 | USD -62,642 | The ETF sold 560 shares of RYTM on 2025-12-17. The shares were previously bought for an average price of USD 83.781. The Rhythm Pharmaceuticals Inc shares were sold for 33.5% higher than average price of previous purchases. This sale made a profit of USD 15,724 The average price that the ETF previously sold RYTM share for is USD 64.4784 so the ETF has sold 560 shares on 2025-12-17 at a higher price than the previous selling average. |
| HALO - Halozyme Therapeutics Inc | SELL | -980 @ USD 65.77 | USD -64,455 | The ETF sold 980 shares of HALO on 2025-12-17. The shares were previously bought for an average price of USD 61.4961. The Halozyme Therapeutics Inc shares were sold for 6.9% higher than average price of previous purchases. This sale made a profit of USD 4,188 The average price that the ETF previously sold HALO share for is USD 59.6256 so the ETF has sold 980 shares on 2025-12-17 at a higher price than the previous selling average. |
| ARWR - Arrowhead Pharmaceuticals Inc | SELL | -1,160 @ USD 64.8 | USD -75,168 | The ETF sold 1160 shares of ARWR on 2025-12-17. The shares were previously bought for an average price of USD 30.2525. The Arrowhead Pharmaceuticals Inc shares were sold for 114.2% higher than average price of previous purchases. This sale made a profit of USD 40,075 The average price that the ETF previously sold ARWR share for is USD 21.2344 so the ETF has sold 1160 shares on 2025-12-17 at a higher price than the previous selling average. |
| BNTX - BioNTech SE | SELL | -850 @ USD 91.6 | USD -77,860 | The ETF sold 850 shares of BNTX on 2025-12-17. The shares were previously bought for an average price of USD 103.084. The BioNTech SE shares were sold for -11.1% lower than average price of previous purchases. This resulted in an overall loss of USD 9,761 The average price that the ETF previously sold BNTX share for is USD 104.122 which is higher than the selling price of USD 91.6 on 2025-12-17. |
| RNA - Avidity Biosciences Inc | SELL | -1,085 @ USD 71.87 | USD -77,979 | The ETF sold 1085 shares of RNA on 2025-12-17. The shares were previously bought for an average price of USD 46.9429. The Avidity Biosciences Inc shares were sold for 53.1% higher than average price of previous purchases. This sale made a profit of USD 27,046 The average price that the ETF previously sold RNA share for is USD 34.7024 so the ETF has sold 1085 shares on 2025-12-17 at a higher price than the previous selling average. |
| BMRN - Biomarin Pharmaceutical Inc | SELL | -1,615 @ USD 51.8 | USD -83,657 | The ETF sold 1615 shares of BMRN on 2025-12-17. The shares were previously bought for an average price of USD 57.0929. The Biomarin Pharmaceutical Inc shares were sold for -9.3% lower than average price of previous purchases. This resulted in an overall loss of USD 8,548 The average price that the ETF previously sold BMRN share for is USD 61.5775 which is higher than the selling price of USD 51.8 on 2025-12-17. |
| JAZZ - Jazz Pharmaceuticals PLC | SELL | -510 @ USD 164.915 | USD -84,107 | The ETF sold 510 shares of JAZZ on 2025-12-17. The shares were previously bought for an average price of USD 135.407. The Jazz Pharmaceuticals PLC shares were sold for 21.8% higher than average price of previous purchases. This sale made a profit of USD 15,049 The average price that the ETF previously sold JAZZ share for is USD 124.648 so the ETF has sold 510 shares on 2025-12-17 at a higher price than the previous selling average. |
| EXEL - Exelixis Inc | SELL | -2,265 @ USD 42 | USD -95,130 | The ETF sold 2265 shares of EXEL on 2025-12-17. The shares were previously bought for an average price of USD 41.6794. The Exelixis Inc shares were sold for 0.8% higher than average price of previous purchases. This sale made a profit of USD 726 The average price that the ETF previously sold EXEL share for is USD 36.5968 so the ETF has sold 2265 shares on 2025-12-17 at a higher price than the previous selling average. |
| MRNA - Moderna Inc | SELL | -3,275 @ USD 30.51 | USD -99,920 | The ETF sold 3275 shares of MRNA on 2025-12-17. The shares were previously bought for an average price of USD 28.1569. The Moderna Inc shares were sold for 8.4% higher than average price of previous purchases. This sale made a profit of USD 7,706 The average price that the ETF previously sold MRNA share for is USD 33.2376 which is higher than the selling price of USD 30.51 on 2025-12-17. |
| MDGL - Madrigal Pharmaceuticals Inc | SELL | -185 @ USD 546.19 | USD -101,045 | The ETF sold 185 shares of MDGL on 2025-12-17. The shares were previously bought for an average price of USD 411.281. The Madrigal Pharmaceuticals Inc shares were sold for 32.8% higher than average price of previous purchases. This sale made a profit of USD 24,958 The average price that the ETF previously sold MDGL share for is USD 345.656 so the ETF has sold 185 shares on 2025-12-17 at a higher price than the previous selling average. |
| GH - Guardant Health Inc | SELL | -1,045 @ USD 97.47 | USD -101,856 | The ETF sold 1045 shares of GH on 2025-12-17. The shares were previously bought for an average price of USD 68.6525. The Guardant Health Inc shares were sold for 42.0% higher than average price of previous purchases. This sale made a profit of USD 30,114 The average price that the ETF previously sold GH share for is USD 43.641 so the ETF has sold 1045 shares on 2025-12-17 at a higher price than the previous selling average. |
| IONS - Ionis Pharmaceuticals Inc | SELL | -1,335 @ USD 77.08 | USD -102,902 | The ETF sold 1335 shares of IONS on 2025-12-17. The shares were previously bought for an average price of USD 56.8592. The Ionis Pharmaceuticals Inc shares were sold for 35.6% higher than average price of previous purchases. This sale made a profit of USD 26,995 The average price that the ETF previously sold IONS share for is USD 42.0255 so the ETF has sold 1335 shares on 2025-12-17 at a higher price than the previous selling average. |
| ASND - Ascendis Pharma AS | SELL | -510 @ USD 202.82 | USD -103,438 | The ETF sold 510 shares of ASND on 2025-12-17. The shares were previously bought for an average price of USD 186.345. The Ascendis Pharma AS shares were sold for 8.8% higher than average price of previous purchases. This sale made a profit of USD 8,402 The average price that the ETF previously sold ASND share for is USD 157.713 so the ETF has sold 510 shares on 2025-12-17 at a higher price than the previous selling average. |
| SMMT - Summit Therapeutics PLC | SELL | -6,250 @ USD 17.01 | USD -106,313 | The ETF sold 6250 shares of SMMT on 2025-12-17. The shares were previously bought for an average price of USD 20.4764. The Summit Therapeutics PLC shares were sold for -16.9% lower than average price of previous purchases. This resulted in an overall loss of USD 21,665 The average price that the ETF previously sold SMMT share for is USD 19.8902 which is higher than the selling price of USD 17.01 on 2025-12-17. |
| SNY - Sanofi ADR | SELL | -2,260 @ USD 48.14 | USD -108,796 | The ETF sold 2260 shares of SNY on 2025-12-17. The shares were previously bought for an average price of USD 49.8689. The Sanofi ADR shares were sold for -3.5% lower than average price of previous purchases. This resulted in an overall loss of USD 3,907 The average price that the ETF previously sold SNY share for is USD 49.8341 which is higher than the selling price of USD 48.14 on 2025-12-17. |
| VTRS - Viatris Inc | SELL | -9,780 @ USD 11.7 | USD -114,426 | The ETF sold 9780 shares of VTRS on 2025-12-17. The shares were previously bought for an average price of USD 9.92002. The Viatris Inc shares were sold for 17.9% higher than average price of previous purchases. This sale made a profit of USD 17,408 The average price that the ETF previously sold VTRS share for is USD 10.5019 so the ETF has sold 9780 shares on 2025-12-17 at a higher price than the previous selling average. |
| NBIX - Neurocrine Biosciences Inc | SELL | -835 @ USD 141.7 | USD -118,319 | The ETF sold 835 shares of NBIX on 2025-12-17. The shares were previously bought for an average price of USD 135.725. The Neurocrine Biosciences Inc shares were sold for 4.4% higher than average price of previous purchases. This sale made a profit of USD 4,989 The average price that the ETF previously sold NBIX share for is USD 126.043 so the ETF has sold 835 shares on 2025-12-17 at a higher price than the previous selling average. |
| BBIO - BridgeBio Pharma Inc | SELL | -1,610 @ USD 74.02 | USD -119,172 | The ETF sold 1610 shares of BBIO on 2025-12-17. The shares were previously bought for an average price of USD 52.1831. The BridgeBio Pharma Inc shares were sold for 41.8% higher than average price of previous purchases. This sale made a profit of USD 35,157 The average price that the ETF previously sold BBIO share for is USD 35.6791 so the ETF has sold 1610 shares on 2025-12-17 at a higher price than the previous selling average. |
| RVMD - Revolution Medicines Inc | SELL | -1,575 @ USD 76.74 | USD -120,865 | The ETF sold 1575 shares of RVMD on 2025-12-17. The shares were previously bought for an average price of USD 50.1446. The Revolution Medicines Inc shares were sold for 53.0% higher than average price of previous purchases. This sale made a profit of USD 41,888 The average price that the ETF previously sold RVMD share for is USD 43.4237 so the ETF has sold 1575 shares on 2025-12-17 at a higher price than the previous selling average. |
| ROIV - Roivant Sciences Ltd | SELL | -5,725 @ USD 22.7 | USD -129,958 | The ETF sold 5725 shares of ROIV on 2025-12-17. The shares were previously bought for an average price of USD 15.2175. The Roivant Sciences Ltd shares were sold for 49.2% higher than average price of previous purchases. This sale made a profit of USD 42,837 The average price that the ETF previously sold ROIV share for is USD 11.9201 so the ETF has sold 5725 shares on 2025-12-17 at a higher price than the previous selling average. |
| MEDP - Medpace Holdings Inc | SELL | -235 @ USD 557.07 | USD -130,911 | The ETF sold 235 shares of MEDP on 2025-12-17. The shares were previously bought for an average price of USD 445.12. The Medpace Holdings Inc shares were sold for 25.2% higher than average price of previous purchases. This sale made a profit of USD 26,308 The average price that the ETF previously sold MEDP share for is USD 365.849 so the ETF has sold 235 shares on 2025-12-17 at a higher price than the previous selling average. |
| RPRX - Royalty Pharma Plc | SELL | -3,635 @ USD 38.31 | USD -139,257 | The ETF sold 3635 shares of RPRX on 2025-12-17. The shares were previously bought for an average price of USD 36.708. The Royalty Pharma Plc shares were sold for 4.4% higher than average price of previous purchases. This sale made a profit of USD 5,823 The average price that the ETF previously sold RPRX share for is USD 30.2576 so the ETF has sold 3635 shares on 2025-12-17 at a higher price than the previous selling average. |
| INCY - Incyte Corporation | SELL | -1,640 @ USD 97.63 | USD -160,113 | The ETF sold 1640 shares of INCY on 2025-12-17. The shares were previously bought for an average price of USD 81.6071. The Incyte Corporation shares were sold for 19.6% higher than average price of previous purchases. This sale made a profit of USD 26,278 The average price that the ETF previously sold INCY share for is USD 72.4286 so the ETF has sold 1640 shares on 2025-12-17 at a higher price than the previous selling average. |
| ILMN - Illumina Inc | SELL | -1,290 @ USD 129.56 | USD -167,132 | The ETF sold 1290 shares of ILMN on 2025-12-17. The shares were previously bought for an average price of USD 105.819. The Illumina Inc shares were sold for 22.4% higher than average price of previous purchases. This sale made a profit of USD 30,626 The average price that the ETF previously sold ILMN share for is USD 106.629 so the ETF has sold 1290 shares on 2025-12-17 at a higher price than the previous selling average. |
| UTHR - United Therapeutics Corporation | SELL | -380 @ USD 510.94 | USD -194,157 | The ETF sold 380 shares of UTHR on 2025-12-17. The shares were previously bought for an average price of USD 380.392. The United Therapeutics Corporation shares were sold for 34.3% higher than average price of previous purchases. This sale made a profit of USD 49,608 The average price that the ETF previously sold UTHR share for is USD 352.789 so the ETF has sold 380 shares on 2025-12-17 at a higher price than the previous selling average. |
| BIIB - Biogen Inc | SELL | -1,230 @ USD 172.1 | USD -211,683 | The ETF sold 1230 shares of BIIB on 2025-12-17. The shares were previously bought for an average price of USD 149.071. The Biogen Inc shares were sold for 15.4% higher than average price of previous purchases. This sale made a profit of USD 28,326 The average price that the ETF previously sold BIIB share for is USD 143.15 so the ETF has sold 1230 shares on 2025-12-17 at a higher price than the previous selling average. |
| ARGX - argenx NV ADR | SELL | -255 @ USD 862.05 | USD -219,823 | The ETF sold 255 shares of ARGX on 2025-12-17. The shares were previously bought for an average price of USD 715.907. The argenx NV ADR shares were sold for 20.4% higher than average price of previous purchases. This sale made a profit of USD 37,266 The average price that the ETF previously sold ARGX share for is USD 637.317 so the ETF has sold 255 shares on 2025-12-17 at a higher price than the previous selling average. |
| INSM - Insmed Inc | SELL | -1,775 @ USD 198.46 | USD -352,267 | The ETF sold 1775 shares of INSM on 2025-12-17. The shares were previously bought for an average price of USD 141.595. The Insmed Inc shares were sold for 40.2% higher than average price of previous purchases. This sale made a profit of USD 100,935 The average price that the ETF previously sold INSM share for is USD 88.3065 so the ETF has sold 1775 shares on 2025-12-17 at a higher price than the previous selling average. |
| AZN - AstraZeneca PLC | SELL | -4,350 @ USD 89.86 | USD -390,891 | The ETF sold 4350 shares of AZN on 2025-12-17. The shares were previously bought for an average price of USD 78.7875. The AstraZeneca PLC shares were sold for 14.1% higher than average price of previous purchases. This sale made a profit of USD 48,165 The average price that the ETF previously sold AZN share for is USD 72.0401 so the ETF has sold 4350 shares on 2025-12-17 at a higher price than the previous selling average. |
| ALNY - Alnylam Pharmaceuticals Inc | SELL | -1,090 @ USD 392.1 | USD -427,389 | The ETF sold 1090 shares of ALNY on 2025-12-17. The shares were previously bought for an average price of USD 395.411. The Alnylam Pharmaceuticals Inc shares were sold for -0.8% lower than average price of previous purchases. This resulted in an overall loss of USD 3,609 The average price that the ETF previously sold ALNY share for is USD 280.5 so the ETF has sold 1090 shares on 2025-12-17 at a higher price than the previous selling average. |
| REGN - Regeneron Pharmaceuticals Inc | SELL | -870 @ USD 749.79 | USD -652,317 | The ETF sold 870 shares of REGN on 2025-12-17. The shares were previously bought for an average price of USD 649.194. The Regeneron Pharmaceuticals Inc shares were sold for 15.5% higher than average price of previous purchases. This sale made a profit of USD 87,519 The average price that the ETF previously sold REGN share for is USD 624.458 so the ETF has sold 870 shares on 2025-12-17 at a higher price than the previous selling average. |
| GILD - Guild Esports Plc | SELL | -6,155 @ USD 121.36 | USD -746,971 | The ETF sold 6155 shares of GILD on 2025-12-17. The shares were previously bought for an average price of USD 115.871. The Guild Esports Plc shares were sold for 4.7% higher than average price of previous purchases. This sale made a profit of USD 33,785 The average price that the ETF previously sold GILD share for is USD 101.705 so the ETF has sold 6155 shares on 2025-12-17 at a higher price than the previous selling average. |
| AMGN - Amgen Inc | SELL | -2,415 @ USD 326.01 | USD -787,314 | The ETF sold 2415 shares of AMGN on 2025-12-17. The shares were previously bought for an average price of USD 299.477. The Amgen Inc shares were sold for 8.9% higher than average price of previous purchases. This sale made a profit of USD 64,077 The average price that the ETF previously sold AMGN share for is USD 302.743 so the ETF has sold 2415 shares on 2025-12-17 at a higher price than the previous selling average. |
| VRTX - Vertex Pharmaceuticals Inc | SELL | -1,780 @ USD 449.52 | USD -800,146 | The ETF sold 1780 shares of VRTX on 2025-12-17. The shares were previously bought for an average price of USD 421.965. The Vertex Pharmaceuticals Inc shares were sold for 6.5% higher than average price of previous purchases. This sale made a profit of USD 49,048 The average price that the ETF previously sold VRTX share for is USD 469.545 which is higher than the selling price of USD 449.52 on 2025-12-17. |